Inflammatory Markers and Outcomes after Lacunar Stroke: Levels of Inflammatory Markers in Treatment of Stroke Study

Stroke

Volumn 47, Issue 3, 2016, Pages 659-667

  Boehme, Amelia K ^a,b   McClure, Leslie A ^c   Zhang, Yu ^d   Luna, Jorge M ^a   Del Brutto, Oscar H ^e   Benavente, Oscar R ^f   Elkind, Mitchell S V ^a,b  

^a Columbia University ^*  (United States)

^b Department of Medicine   (United States)

^c DREXEL UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSIDAD ESPÍRITU SANTO   (Ecuador)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Inflammation; interleukin 6; lacunar stroke; prognosis; stroke

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CD40 LIGAND; CLOPIDOGREL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; AUTACOID; IL6 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGED; ANTICOAGULANT THERAPY; BRAIN ISCHEMIA; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DRUG USE; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; LACUNAR STROKE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENCE RISK; BLOOD; CLINICAL TRIAL; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RISK FACTOR; STROKE, LACUNAR; TREATMENT OUTCOME;

AGED; BIOMARKERS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RISK FACTORS; STROKE, LACUNAR; TREATMENT OUTCOME;

EID: 84959563321     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.012166     Document Type: Conference Paper

References (33)

1. Chamorro A, Sacco RL, Mohr JP, Foulkes MA, Kase CS, Tatemichi TK, et al. Clinical-computed tomographic correlations of lacunar infarction in the stroke data bank. Stroke. 1991;22:175-181.
2. Rothrock JF, Lyden PD, Brody ML, Taft-Alvarez B, Kelly N, Mayer J, et al. An analysis of ischemic stroke in an urban Southern California population. The University of California, San Diego, Stroke Data Bank. Arch Intern Med. 1993;153:619-624.
3. Wolfe CD, Rudd AG, Howard R, Coshall C, Stewart J, Lawrence E, et al. Incidence and case fatality rates of stroke subtypes in a multiethnic population: The South London Stroke Register. J Neurol Neurosurg Psychiatry. 2002;72:211-216.
4. Gorelick PB, Caplan LR, Hier DB, Parker SL, Patel D. Racial differences in the distribution of anterior circulation occlusive disease. Neurology. 1984;34:54-59.
5. Ross GW, Petrovitch H, White LR, Masaki KH, Li CY, Curb JD, et al. Characterization of risk factors for vascular dementia: the Honolulu-Asia Aging Study. Neurology. 1999;53:337-343.
6. Tatemichi TK, Desmond DW, Paik M, Figueroa M, Gropen TI, Stern Y, et al. Clinical determinants of dementia related to stroke. Ann Neurol. 1993;33:568-575. doi: 10.1002/ana.410330603.
7. Fisher CM. Cerebral ischemia-less familiar types. Clin Neurosurg. 1971;18:267-336.
8. Fisher CM. Capsular infarcts: the underlying vascular lesions. Arch Neurol. 1979;36:65-73.
9. Fisher CM. Thalamic pure sensory stroke: a pathologic study. Neurology. 1978;28:1141-1144.
10. Sacco RL. Risk factors, outcomes, and stroke subtypes for ischemic stroke. Neurology. 1997;49(5 suppl 4):S39-S44.
11. Tuttolomondo A, Di Raimondo D, Di Sciacca R, Pecoraro R, Arnao V, Buttà C, et al. Arterial stiffness and ischemic stroke in subjects with and without metabolic syndrome. Atherosclerosis. 2012;225:216-219. doi: 10.1016/j.atherosclerosis.2012.08.027.
12. Pinto A, Tuttolomondo A, Casuccio A, Di Raimondo D, Di Sciacca R, Arnao V, et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond). 2009;116:781-789. doi: 10.1042/CS20080372.
13. Revilla M, Obach V, Cervera A, Davalos A, Castillo J, Chamorro A. A-174g/c polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci Lett. 2002;324:29-32.
14. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
15. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843. doi: 10.1056/NEJM200003233421202.
16. Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, et al; SPS Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012;367:817-825.
17. Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, et al; SPSS Investigators. Blood-pressure targets in patients with recent lacunar stroke: The SPS3 Randomised Trial. Lancet. 2013;382:507-515.
18. Elkind MS, Luna JM, McClure LA, Zhang Y, Coffey CS, Roldan A, et al; LIMITS Investigators. C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study. Stroke. 2014;45:707-716. doi: 10.1161/STROKEAHA.113.004562.
19. Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, et al; SPS3 Investigators. The secondary prevention of small subcortical strokes (SPS3) study. Int J Stroke. 2011;6:164-175. doi: 10.1111/j.1747-4949.2010.00573.x.
20. Elkind MS, Luna JM, Coffey CS, McClure LA, Liu KM, Spitalnik S, et al. The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke. Int J Stroke. 2010;5:117-125. doi: 10.1111/j.1747-4949.2010.00420.x.
21. Samuelsson M, Soderfeldt B, Olsson GB. Functional outcome in patients with lacunar infarction. Stroke. 1996;27:842-846.
22. Whiteley W, Jackson C, Lewis S, Lowe G, Rumley A, Sandercock P, et al. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med. 2009;6:e1000145. doi: 10.1371/journal.pmed.1000145.
23. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Monaco C, et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94:874-877.
24. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31:2325-2329.
25. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol. 1995;37:800-805. doi: 10.1002/ana.410370614.
26. Luna JM, Moon YP, Liu KM, Spitalnik S, Paik MC, Cheung K, et al. High-sensitivity C-reactive protein and interleukin-6-dominant inflammation and ischemic stroke risk: the northern Manhattan study. Stroke. 2014;45:979-987. doi: 10.1161/STROKEAHA.113.002289.
27. Luna JM, Moon Y, Liu K, Spitalnik S, Paik M, Sacco R, et al. Tumour necrosis factor receptor 1 and mortality in a multi-ethnic cohort: the Northern Manhattan Study. Age Ageing. 2013;42:385-390. doi: 10.1093/ageing/afs175.
28. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004;351:2599-2610. doi: 10.1056/NEJMoa040967.
29. Elkind MS, Cheng J, Boden-Albala B, Rundek T, Thomas J, Chen H, et al. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke. 2002;33:31-37.
30. Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, et al. Inflammation-mediated damage in progressing lacunar infarctions: A potential therapeutic target. Stroke. 2002;33:982-987.
31. Doyle KP, Quach LN, Solé M, Axtell RC, Nguyen TV, Soler-Llavina GJ, et al. B-lymphocyte-mediated delayed cognitive impairment following stroke. J Neurosci. 2015;35:2133-2145. doi: 10.1523/JNEUROSCI.4098-14.2015.
32. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979. doi: 10.1056/NEJM199704033361401.
33. Di Napoli M, Schwaninger M, Cappelli R, Ceccarelli E, Di Gianfilippo G, Donati C, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005;36:1316-1329. doi: 10.1161/01. STR.0000165929.78756.ed.